About ADC Therapeutics
ADC Therapeutics is a company based in Epalinges (Switzerland) founded in 2011 by Stephen Evans Freke.. ADC Therapeutics has raised $641 million across 8 funding rounds from investors including Astrazeneca, MedImmune and Deerfield. The company has 265 employees as of December 31, 2024. ADC Therapeutics offers products and services including ZYNLONTA, loncastuximab tesirine-lpyl, and ADCT-602. ADC Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Epalinges, Switzerland
- Employees 265 as on 31 Dec, 2024
- Founders Stephen Evans Freke
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adc Therapeutics Sa
-
Annual Revenue
$70.84 M1.84as on Dec 31, 2024
-
Net Profit
$-157.85 M34.25as on Dec 31, 2024
-
EBITDA
$-127.38 M20.94as on Dec 31, 2024
-
Total Equity Funding
$641 M (USD)
in 8 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
May 17, 2021
-
Investors
Astrazeneca
& 4 more
-
Employee Count
265
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ADC Therapeutics
ADC Therapeutics is a publicly listed company on the NYSE with ticker symbol ADCT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ADC Therapeutics
ADC Therapeutics offers a comprehensive portfolio of products and services, including ZYNLONTA, loncastuximab tesirine-lpyl, and ADCT-602. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antibody drug conjugate targeting lymphoma and other cancers.
Antibody drug for cancer research and potential therapies.
Experimental antibody drug conjugate for oncology applications.
Unlock access to complete
Unlock access to complete
Leadership Team
47 people
Human Resources and Administration
8 people
Senior Team
8 people
Sales and Marketing
6 people
Finance and Accounting
6 people
Legal and Compliance
6 people
Software Development Team
5 people
Hematology Team
4 people
Unlock access to complete
Funding Insights of ADC Therapeutics
ADC Therapeutics has successfully raised a total of $641M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(15 Oct 2013)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Post-IPO - ADC Therapeutics | Valuation |
investors |
|
| Apr, 2020 | Amount | Series E - ADC Therapeutics | Valuation |
investors |
|
| Jul, 2019 | Amount | Series E - ADC Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ADC Therapeutics
ADC Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, MedImmune and Deerfield. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Pharmaceutical and biologics products are developed and distributed worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ADC Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ADC Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adc Therapeutics Comparisons
Competitors of ADC Therapeutics
ADC Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adc Therapeutics
Frequently Asked Questions about ADC Therapeutics
When was ADC Therapeutics founded?
ADC Therapeutics was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Where is ADC Therapeutics located?
ADC Therapeutics is headquartered in Epalinges, Switzerland. It is registered at Epalinges, Vaud, Switzerland.
Is ADC Therapeutics a funded company?
ADC Therapeutics is a funded company, having raised a total of $641M across 8 funding rounds to date. The company's 1st funding round was a Series E of $25M, raised on Oct 15, 2013.
How many employees does ADC Therapeutics have?
As of Dec 31, 2024, the latest employee count at ADC Therapeutics is 265.
What is the annual revenue of ADC Therapeutics?
Annual revenue of ADC Therapeutics is $70.84M as on Dec 31, 2024.
What does ADC Therapeutics do?
ADC Therapeutics was founded in 2011 and is headquartered in Epalinges, Switzerland. Antibody-drug conjugates are developed by the company for oncology applications. The lead product, Zynlonta, is approved for relapsed or refractory large B-cell lymphoma in adults. Additional candidates include ADCT-602 for B-cell acute lymphoblastic leukemia, and ADCT-901 for ovarian and triple-negative breast cancers. Operations focus on advancing targeted therapies in the biopharmaceutical sector.
Who are the top competitors of ADC Therapeutics?
ADC Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does ADC Therapeutics offer?
ADC Therapeutics offers ZYNLONTA, loncastuximab tesirine-lpyl, and ADCT-602.
Is ADC Therapeutics publicly traded?
Yes, ADC Therapeutics is publicly traded on NYSE under the ticker symbol ADCT.
Who are ADC Therapeutics's investors?
ADC Therapeutics has 5 investors. Key investors include Astrazeneca, MedImmune, Deerfield, Auven Therapeutics, and Redmile Group.
What is ADC Therapeutics's ticker symbol?
The ticker symbol of ADC Therapeutics is ADCT on NYSE.